Emmis Acquisition (EMIS) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Emmis Acquisition (EMIS) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 4.4% versus a loss of 11.9%. Emmis Acquisition is the larger company by market cap ($163.4 million vs $153.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EMIS | IFRX |
|---|---|---|
| Share price | $10.36 | $1.04 |
| Market cap | $163.36M | $153.26M |
| 1-day change | +0.15% | -4.59% |
| YTD return | +4.07% | +2.97% |
| 1-year return | +4.39% | -11.86% |
| 5-year return | — | -79.53% |
| EPS (TTM) | — | $-0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.38 | $2.95 |
| 52-week low | $9.92 | $0.798 |
| Distance from 52-week high | -0.24% | -64.73% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +696.15% |
| Average volume | 16.19K | 868.66K |
| Shares outstanding | 11.94M | 147.37M |
| Employees | — | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EMIS has outperformed IFRX by 16.2 percentage points over the past year.
About Emmis Acquisition
EMIS stock →Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
Health Care · Biotechnology: Pharmaceutical Preparations
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
EMIS vs IFRX FAQ
Which is bigger, Emmis Acquisition or InflaRx N.V.?
Emmis Acquisition (EMIS) is larger, with a market capitalization of $163.36M compared with $153.26M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, EMIS or IFRX?
EMIS returned +4.39% over the past 12 months, compared with -11.86% for IFRX (price return, excluding dividends). Past performance does not predict future results.
Are Emmis Acquisition and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.